SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
ICOS Corporation
An SI Board Since May 1996
Posts SubjectMarks Bans Symbol
1139 66 0 ICOS
Emcee:  Gerald R. Lampton Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
864New coverage (Buy) initiated by CSFB biz.yahoo.comSemiBull-11/14/2001
863Sounds like an oxymoron to me... :^) <i><b>...the fast-growing ereIan@SI-11/14/2001
862The ED market is still a humorous one, intentionally or not (see emphasis, whichtuck-11/14/2001
861Deleted; stupid posting server. Please click "Next."tuck-11/14/2001
860New Coverage for ICOS: Morgan Stanley to Outperform CSFB to Buy biz.yahoo.SemiBull-11/13/2001
859ICOS Corporation Announces Pricing of Public Offering of Common Stock biz.yahoo.SemiBull-11/8/2001
858ICOS Acquires Rights to Afferon's RTX For Treatment of Urological Disorders SemiBull-11/5/2001
857ICOS announces offering of 4.5 million common shares biz.yahoo.comSemiBull-11/1/2001
856ICOS Corporation [ICOS $55.00] 12-Month Price Target: $68.00 2001E EPS: ($1.50Icebrg-10/25/2001
855ICOS posts wider third-quarter loss biz.yahoo.comSemiBull-10/24/2001
854And WSJ FDA Advisers Are Split In Voting on Lilly Drug By OTESA MIDDLETON and Icebrg-10/17/2001
853Financial Times on Lilly's Xigris problems USFDA panel split on Lilly sepsiIcebrg-10/17/2001
852FDA Panel's Rejection of Xigris Comes as a Painful Shock to Lilly thestreetIcebrg-10/17/2001
851First Presentation of Large-Scale Integrated Analysis of Phase III Data on CialiSemiBull-10/2/2001
850Sshhh! Don't tell anyone . . . >>BOTHELL, Wash.--(BUSINESS WIREtuck-9/3/2001
849Array and ICOS Establish Drug Discovery Collaboration Exploiting A Novel ChemicaSemiBull-8/14/2001
848ICOS Reports Results For Second Quarter of 2001 biz.yahoo.comSemiBull-7/26/2001
847Statement to the Media -- European Patent Office Says <b>Pfizer's MethIan@SI-7/18/2001
846CNBC Business Center is spotlighting various Biotechs this week. ICOS will be cIan@SI-7/17/2001
845Rivals to Viagra Are On the Horizon ... Another PDE5 inhibitor may be the next Ian@SI-7/16/2001
844ICOS and Biogen Collaborate to Develop Oral Therapeutics for Autoimmune and InflSemiBull-7/16/2001
843Lilly ICOS Files for European Approval of Cialis to Treat ED BIan@SI-7/12/2001
842ICOS Corp ICOS Prudential reiterates Buy with a $75 price target.Ian@SI-7/2/2001
841ICOS Initiates Enrollment in Phase 1 Clinical Trial With IC747, an LFA-1 AntagonIan@SI-7/2/2001
840ICOS Corp (ICOS) 63.61 +3.66: CE Unterberg Towbin reiterates BUY rating; believeIan@SI-6/28/2001
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News